NCT05285813View on ClinicalTrials.gov

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
AMLMDS
Interventions
DRUG

Vibecotamab

Given by vein (IV)

DRUG

Dexamethasone

Given by vein (IV) over about 60 minutes before the dose

DRUG

Acetaminophen

Given by mouth (PO) about 30-60 minutes before the dose

DRUG

Diphenhydramine

Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER